These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 26003888)

  • 21. Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis.
    Gad H; Hayat T; Al-Muhannadi H; Malik BR; Mussleman P; Malik RA
    Diabetes Res Clin Pract; 2021 Feb; 172():108562. PubMed ID: 33271228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies.
    Abdelrahim D; Faris ME; Hassanein M; Shakir AZ; Yusuf AM; Almeneessier AS; BaHammam AS
    Front Endocrinol (Lausanne); 2021; 12():624423. PubMed ID: 33763029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
    J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical practice points for diabetes management during RAMADAN fast.
    Sadikot S; Jothydev K; Zargar AH; Ahmad J; Arvind SR; Saboo B
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S811-S819. PubMed ID: 28629656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attitude and safety of patients with diabetes observing the Ramadan fast.
    Ba-Essa EM; Hassanein M; Abdulrhman S; Alkhalifa M; Alsafar Z
    Diabetes Res Clin Pract; 2019 Jun; 152():177-182. PubMed ID: 30946851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
    Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
    Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
    Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
    Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
    Hassanein M; Echtay A; Hassoun A; Alarouj M; Afandi B; Poladian R; Bennakhi A; Nazar M; Bergmans P; Keim S; Hamilton G; Azar ST
    Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28851109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment Options for Patients with Type 2 Diabetes Mellitus during the Fasting Month of Ramadan.
    Loh HH; Kamaruddin NA
    Ann Acad Med Singap; 2020 Jul; 49(7):468-476. PubMed ID: 33000110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan.
    Zargar A; Basit A; Mahtab H
    J Indian Med Assoc; 2005 Aug; 103(8):444-6. PubMed ID: 16363203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial.
    Hassanein MM; Sahay R; Hafidh K; Djaballah K; Li H; Azar S; Shehadeh N; Hanif W
    Diabetes Res Clin Pract; 2019 Apr; 150():331-341. PubMed ID: 30772385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes.
    Abdelgadir E; Rashid F; Bashier A; Al Saeed M; Khalifa A; Alawadi F; Hassanein M
    Diabetes Metab Syndr; 2019; 13(5):2927-2932. PubMed ID: 31425958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.
    Sari R; Balci MK; Akbas SH; Avci B
    Endocr Res; 2004 May; 30(2):169-77. PubMed ID: 15473127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does Reducing Basal Insulin During Ramadan Fasting by Children and Adolescents with Type 1 Diabetes Decrease the Risk of Symptomatic Hypoglycemia?
    Deeb A; Al Qahtani N; Attia S; Al Suwaidi H; Nagelkerke N
    Diabetes Technol Ther; 2016 Sep; 18(9):539-42. PubMed ID: 27500913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast.
    Zargar AH; Siraj M; Jawa AA; Hasan M; Mahtab H
    Int J Clin Pract; 2010 Jul; 64(8):1090-4. PubMed ID: 20455956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and effectiveness of iGlarLixi in adults with type 2 diabetes mellitus from Gulf countries during Ramadan holy month: A subgroup analysis of the SoliRam observational study.
    Hassanein M; El Naggar A; Al Sheikh A; Djaballah K; Saeed M; Melas-Melt L; AlSifri S
    Diabetes Res Clin Pract; 2024 Mar; 209():111567. PubMed ID: 38341039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ramadan Perspective Epidemiology and Education in Diabetes (RAPEED) Study.
    Siddiqui NI; Kamrul-Hasan M; Hossain MA; Chanda PK; Bakar MA; Rahman M; Kader MA
    Mymensingh Med J; 2017 Apr; 26(2):256-265. PubMed ID: 28588159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.